Rhonda Hewitt, NP
Nurse Practitioner · Stanford, CANPI 1649289943
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $650,386 of the $917,039 with a category attached, or 70.9%. 29 manufacturers reported payments, led by Johnson & Johnson at 49.1% of the total. Among nurse practitioner clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,936 payments — averaging $473.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$451K
- Amgen$125K
- AstraZeneca$89K
- Incyte Corporation$74K
- Pharmacyclics LLC, An Abbvie Company$65K
- Beone Medicines USA, Inc.$26K
- plus $89K from 23 others
What the payments were for
- Consulting fees$17,8892%
- Speaking & faculty fees$650,38671%
- Travel & lodging$206,87223%
- Food & beverage$41,7935%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 875 | $450,584 |
| Amgen | 294 | $124,859 |
| AstraZeneca | 153 | $88,909 |
| Incyte Corporation | 196 | $73,630 |
| Pharmacyclics LLC, An Abbvie Company | 141 | $64,632 |
| Beone Medicines USA, Inc. | 46 | $25,632 |
| Beigene USA, Inc. | 39 | $22,419 |
| GSK | 37 | $22,188 |
| Adaptive Biotechnologies Corporation | 26 | $12,480 |
| Servier Pharmaceuticals LLC | 33 | $12,002 |
| Syndax Pharmaceuticals, Inc. | 22 | $9,734 |
| Sanofi | 7 | $5,166 |
| E.r. Squibb & Sons, L.L.C. | 5 | $1,187 |
| Janssen Global Services, LLC | 1 | $1,060 |
| Bristol Myers Squibb | 4 | $770 |
| AbbVie | 16 | $540 |
| Rigel Pharmaceuticals, Inc. | 7 | $251 |
| Pharmaessentia USA Corporation | 7 | $208 |
| Gilead | 7 | $177 |
| Merck | 5 | $137 |
| Janssen Scientific Affairs, LLC | 2 | $96 |
| Daiichi Sankyo Inc. | 3 | $84 |
| Regeneron Healthcare Solutions, Inc. | 3 | $73 |
| Geron Corporation | 1 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Legend Biotech USA Inc. | 1 | $35 |
| Stemline Therapeutics Inc. | 1 | $29 |
| CTI Biopharma Corp. | 1 | $28 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$917,040 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 42 | $724,129 |
| RevlimidLenalidomide | 37 | $715,051 |
| ImbruvicaIbrutinib | 34 | $584,882 |
| VenclextaVenetoclax | 27 | $314,960 |
| BrukinsaZanubrutinib | 23 | $281,782 |
| Lenalidomide | 17 | $247,225 |
| CalquenceAcalabrutinib Maleate | 15 | $230,519 |
| BosulifBosutinib | 14 | $225,543 |
| PromactaEltrombopag Olamine | 11 | $203,692 |
| EliquisApixaban | 40 | $30,336 |
| Imatinib Mesylate | 11 | $27,295 |
| Hydroxyurea | 29 | $666 |
| Acyclovir | 23 | $630 |
| Levofloxacin | 11 | $254 |
| Dexamethasone | 12 | $153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $73,630 | $724,12942 claims |
| Bristol Myers SquibbRevlimid | $770 | $715,05137 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $64,632 | $584,88234 claims |
| AbbVieVenclexta | $540 | $314,96027 claims |
| Beigene USA, Inc.Brukinsa | $22,419 | $281,78223 claims |
| AstraZenecaCalquence | $88,909 | $230,51915 claims |
| NovartisPromacta | $13 | $203,69211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Stanford
- Hamta ZareStanford$428K
- Theresa Mallick-SearleStanford$193K
- Martina SpeightStanford$170K
- Helen ShihStanford$104K
- Connie WolfordStanford$69K
- Michelle GapayStanford$37K
- Elaine JangStanford$32K
- Linda TrinhIrvine$884K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.